ATF4靶向RET降解并是甲状腺髓样癌的候选抑癌基因
该研究在小鼠中敲除Atf4导致C细胞增生(MTC癌前病变),并发现ATF4过表达降低MTC细胞存活、阻断RET下游信号通路,且通过促进RET泛素化降低RET蛋白水平。在52%的MTC肿瘤(n=39)中ATF4表达降低或缺失,ATF4低表达与MTC患者总生存期差相关。
要点
- 小鼠Atf4靶向缺失引起C细胞增生,为MTC的癌前病变。
- ATF4过表达降低MTC细胞存活并阻断RET下游信号通路(磷酸化ERK、磷酸化AKT和p70S6K)。
- 52%的MTC肿瘤(n=39)中ATF4表达降低或缺失,且ATF4低表达与总生存期差相关。
核心结论
- ATF4被鉴定为RET的负调控因子、候选抑癌基因,并可能是区分MTC高危患者与预后较好患者的分子标志物。
研究设计与样本
- 研究采用小鼠Atf4靶向缺失评估ATF4在甲状腺中的功能,并通过腺病毒和慢病毒载体实现ATF4过表达;对MTC肿瘤进行免疫组化分析和蛋白质印迹以检测RET和ATF4蛋白水平,采用Kaplan-Meier法分析其与临床结局的关联。
主要发现
- 小鼠Atf4靶向缺失引起C细胞增生,为MTC的癌前病变。
- 强制ATF4表达降低MTC细胞存活并阻断RET下游信号通路(磷酸化ERK、磷酸化AKT和p70S6K)的激活。
- ATF4敲低降低了对酪氨酸激酶抑制剂诱导的凋亡的敏感性。
- ATF4表达通过促进RET泛素化降低RET蛋白水平。
- 与正常甲状腺滤泡细胞相比,52%的MTC肿瘤(n=39)中ATF4表达降低或缺失;MTC肿瘤中RET与ATF4蛋白水平呈负相关,且ATF4低表达与MTC患者总生存期差相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medullary thyroid cancer (MTC) is an aggressive tumor that harbors activating mutations of the RET proto-oncogene. We previously reported that RET inhibits transcriptional activity of ATF4, the master regulator of the stress response pathway, to prevent cell death. OBJECTIVE: We hypothesized that loss of function of ATF4 plays a role in initiation of MTC. DESIGN: Targeted deletion of Atf4 in mice was used to assess ATF4 function in the thyroid gland. ATF4 overexpression was achieved by adenoviral and lentiviral vectors. We used immunohistochemical analysis and western blotting of MTC tumors to determine protein levels of RET and ATF4 and the Kaplan-Meier method to determine their association with clinical outcome. RESULTS: Targeted deletion of Atf4 in mice causes C-cell hyperplasia, a precancerous lesion for MTC. Forced ATF4 expression decreased survival of MTC cells and blocked the activation of RET downstream signaling pathways (phosphorylated ERK, phosphorylated AKT, and p70S6K). ATF4 knockdown decreased sensitivity to tyrosine kinase inhibitor-induced apoptosis. Moreover, ATF4 expression decreased RET protein levels by promoting RET ubiquitination. We found decreased or loss of ATF4 in 52% of MTC tumors (n = 39) compared with normal thyroid follicle cells. A negative correlation was observed between RET and ATF4 protein levels in MTC tumors, and low ATF4 expression was associated with poor overall survival in patients with MTC. CONCLUSIONS: ATF4 was identified as a negative regulator of RET, a candidate tumor suppressor gene, and may be a molecular marker that distinguishes patients at high risk of MTC from those with a longer survival prognosis.
引用
- Bagheri-Yarmand R, Williams MD, Grubbs EG, et al. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 27935748. doi:10.1210/jc.2016-2878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。